Hyperuricemia Market By Drug Class (Xanthine Oxidase Inhibitors, Uricosuric / URAT1 Inhibitors, Uricase-Based Biologics, Anti-Inflammatory Gout Flare Therapies, Combination Therapies); By Clinical Type (Asymptomatic Hyperuricemia, Gout-Associated Symptomatic Hyperuricemia, Refractory / Uncontrolled Gout, Tumor Lysis Syndrome-Associated Hyperuricemia, Uric Acid Stone and Kidney-Associated Hyperuricemia); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hyperuricemia Market: Treatment Gaps and Next-Generation Urate Control Expand a Broad Metabolic Disease Category

The Global Hyperuricemia Market is valued at USD 5.65 billion in 2025 and is projected to reach USD 10.14 billion by 2032, registering a CAGR of 8.7%, according to Strategic Market Research.

 

Xanthine oxidase inhibitors, uricosuric agents, and uricase biologics define the current revenue mix. Allopurinol remains the main long-term oral treatment, while febuxostat serves patients with inadequate response or intolerance. Probenecid increases renal uric acid excretion in selected patients with sufficient kidney function. Pegloticase captures high-value spending in uncontrolled gout after oral therapy failure, whereas rasburicase generates hospital demand in patients at risk of tumor lysis syndrome.

 

Approximately 805 million adults worldwide had hyperuricemia in 2023, including 500 million men and 305 million women. U.S. NHANES data estimated 44.22 million affected adults. Pharmaceutical use, however, is concentrated among the 55.8 million global gout cases recorded in 2020 and approximately 12.1 million U.S. adults with diagnosed gout in 2017–2018. Recurrent attacks, tophi, kidney complications, and failure to reach target serum urate move patients from periodic monitoring into chronic medication, specialist care, or infusion treatment.

 

Late-stage development is increasing competition across both uric acid production and renal excretion pathways. Tigulixostat is advancing as a next-generation xanthine oxidase inhibitor, while ABP-671, dotinurad, and D-0120 target URAT1-mediated urate reabsorption. SEL-212 and NASP combine uricase treatment with immune-tolerance technology intended to limit neutralizing antibodies and extend treatment durability. Dapansutrile targets NLRP3-driven inflammation, positioning it against established medicines used for acute gout flares rather than chronic urate reduction.

 

Biochemical Prevalence Overstates the Drug-Treated Population

Hyperuricemia and gout cannot be treated as interchangeable commercial populations. Elevated serum urate may remain asymptomatic for years, and routine drug therapy is generally not recommended solely because a laboratory result exceeds the reference range. The American College of Rheumatology prioritizes chronic urate-lowering treatment for patients with frequent attacks, tophi, radiographic joint damage, or selected high-risk clinical features. KDIGO guidance similarly does not support using urate-lowering drugs only to slow chronic kidney disease progression in asymptomatic patients.

The addressable market narrows after diagnosis. Some patients require only periodic testing and management of metabolic risk factors. Others enter repeated pharmaceutical use after gout attacks, stone formation, tissue deposition, or persistent disease activity. The result is a broad diagnostic and monitoring base, a smaller recurring oral-treatment population, and a high-value refractory segment requiring specialist or infusion-based care.

Surgery contributes little to total revenue. Procedures are reserved for obstructing stones, severe joint damage, or unusually large and complicated tophi. These interventions treat structural complications rather than serum urate itself, leaving pharmaceuticals, laboratory monitoring, primary care, rheumatology, nephrology, and oncology as the main revenue channels.

 

Kidney Dysfunction and Metabolic Disease Keep the Patient Funnel Expanding

Reduced urate excretion accounts for most hyperuricemia. Kidney impairment, obesity, hypertension, insulin resistance, diuretic exposure, alcohol, fructose-heavy diets, and inherited differences in urate transport all increase the probability that serum urate remains elevated.

U.S. NHANES evidence found that severe obesity was associated with odds ratios of 3.91 in men and 4.76 in women for hyperuricemia. An estimated glomerular filtration rate below 30 was associated with odds ratios of 3.42 in men and 15.37 in women, while diuretic use more than doubled the odds in both sexes. These overlapping conditions increase testing frequency and complicate treatment selection because many patients also require management for hypertension, diabetes, cardiovascular disease, or chronic kidney disease.

Genetic variants involving SLC2A9 and ABCG2 further influence renal and intestinal urate handling. Diet alone may not normalize serum urate in patients with strong genetic, renal, or metabolic drivers. Persistent underexcretion supports long-term demand for xanthine oxidase inhibitors, selective URAT1 inhibitors, combination therapy, and, in severe disease, uricase treatment.

 

Xanthine Oxidase Inhibitors Retain the Largest Revenue Base

Xanthine oxidase inhibitors accounted for 44.2% of market revenue in 2025, equivalent to approximately USD 2.50 billion, and are projected to expand at a CAGR of 7.4% through 2032. Allopurinol supports the segment through guideline preference, generic availability, broad physician familiarity, and use across primary and specialist care. Febuxostat adds second-line revenue among patients who do not respond adequately to allopurinol or cannot tolerate it. Growth remains below the total market because low-priced generics dominate treatment volume.

 

Symptomatic Gout Generates Most Commercial Demand

The gout segment represented an estimated 74.6% of the market in 2025, or approximately USD 4.21 billion, and is expected to grow at a CAGR of 8.4% through 2032. Revenue comes from chronic urate-lowering medication, acute-flare treatment, repeated serum urate testing, specialist consultations, and advanced therapy for uncontrolled disease. Asymptomatic hyperuricemia contributes mainly through laboratory monitoring and selected high-risk treatment, while tumor lysis syndrome and uric acid stone management remain smaller, clinically distinct revenue pools.

 

North America Leads Revenue While Asia Pacific Accelerates

North America held an estimated 42.1% share in 2025, equal to approximately USD 2.38 billion, supported by a large diagnosed gout population, high specialist access, infusion infrastructure, and premium biologic use. Asia Pacific is projected to record the fastest regional CAGR of 10.6% through 2032 as dotinurad expands commercially and Asian developers advance tigulixostat, lingdolinurad, darbinurad, and other selective urate-lowering assets. Treatment thresholds, aging populations, metabolic disease, and wider testing also support regional growth.

 

Allopurinol Controls Treatment Volume but Leaves a Large Control Gap

Allopurinol remains the dominant long-term medicine because it lowers uric acid production, is inexpensive, and can be titrated across a broad patient group. U.S. medication data from 2013–2018 showed that only 28.9% of adults aged 30 or older with diagnosed gout reported current urate-lowering therapy use. Allopurinol accounted for 91.4% of these users, compared with 7.3% for febuxostat and 1.0% for probenecid.

Applying the reported treatment rate to the 12.1 million U.S. gout population gives an approximate treated population of 3.5 million. The larger commercial issue is not only treatment initiation. Many patients discontinue therapy, receive doses that are too low, miss serum urate monitoring, or remain above target despite being prescribed medication.

A global treat-to-target meta-analysis found that 52% of included gout patients received urate-lowering therapy, 50% received it without interruption, 53% underwent serum urate testing, and only 34% reached target. These gaps sustain recurring flares and create demand for dose optimization, adherence support, alternative oral drugs, and stronger agents for patients who remain uncontrolled.

 

Acute-Care Use Reveals Failure of Outpatient Control

Poor urate control also shifts spending into emergency and inpatient care. U.S. data recorded 213,780 emergency-department visits with primary gout in 2014, up from 168,580 in 2006. A separate 2016 inpatient analysis identified 14,135 hospitalizations in which gout was the primary diagnosis. These encounters are expensive consequences of recurrent flares, delayed chronic treatment, and inadequate follow-up rather than the preferred management pathway.

Health systems and payers therefore have a financial reason to support earlier urate-lowering treatment after recurrent attacks, regular serum urate testing, dose escalation, and specialist referral for uncontrolled disease. Fewer flares can reduce rescue medication, urgent consultations, work disruption, and avoidable hospital use while increasing planned outpatient treatment and monitoring.

 

Febuxostat and Selective Uricosurics Compete Beyond First-Line Therapy

Febuxostat serves patients who have an inadequate response to maximally titrated allopurinol, cannot tolerate it, or should not receive it. Its U.S. cardiovascular warning restricts broad first-line use, preserving allopurinol’s volume leadership while maintaining a defined second-line market.

Older uricosurics such as probenecid occupy a smaller position because effectiveness depends on kidney function and treatment can be complicated by drug interactions and stone risk. New selective URAT1 inhibitors aim to improve this treatment class by blocking urate reabsorption more precisely.

Dotinurad has already moved beyond development-stage competition. It was launched in Japan in 2020, approved in China in December 2024, and commercially introduced there in 2025. Its expansion gives physicians another oral option in markets where selective uricosuric treatment is more established and where treatment of high-risk hyperuricemia may be broader than in the United States.

 

Refractory Gout Creates a Small but High-Value Biologic Market

Patients who continue to experience flares, tophi, joint damage, or elevated serum urate despite oral therapy account for a small share of total cases but a disproportionately large share of treatment revenue. Pegloticase converts uric acid into soluble allantoin and is reserved for chronic gout that has not responded to conventional therapy.

Methotrexate co-administration has improved treatment durability by reducing anti-drug antibody formation. The commercial effect is visible in KRYSTEXXA, which generated approximately USD 1.34 billion in 2025 revenue, up 13% year over year. The product demonstrates how specialist-administered therapy can monetize a narrow uncontrolled-gout population at a scale that generic oral products cannot match.

Sobi estimates that more than 200,000 U.S. patients have progressive gout that remains symptomatic or above target after oral therapy, while its narrower uncontrolled-gout opportunity includes approximately 10,000 to 20,000 patients. The funnel narrows sharply, but treatment intensity, repeated infusions, monitoring, and specialist involvement raise revenue per patient.

 

Tumor Lysis Syndrome Sustains a Separate Hospital Market

Tumor lysis syndrome creates acute hyperuricemia when rapid cancer-cell destruction releases large quantities of purines. The resulting uric acid surge can cause acute kidney injury and requires immediate hospital management.

Allopurinol is used preventively in at-risk patients, while rasburicase lowers existing plasma uric acid by converting it into soluble allantoin. Demand is concentrated in oncology centers and hospital pharmacies and depends on cancer type, tumor burden, kidney function, treatment intensity, and institutional prevention protocols. This segment does not depend on gout prevalence and follows oncology treatment volumes rather than community rheumatology patterns.

 

Late-Stage Oral Assets Target Better Urate Control

Tigulixostat, developed by LG Chem and partnered with Innovent in China, is a next-generation xanthine oxidase inhibitor in Phase III development. The program is positioned against established oral inhibitors and targets patients who require stronger urate reduction or improved tolerability during long-term treatment.

Lingdolinurad, previously known as ABP-671, is an oral URAT1 inhibitor from Atom Therapeutics. The company reported positive global Phase IIb/III topline results in 2025, with significant serum urate reduction and continued evaluation of longer-term safety and durability.

Darbinurad, or D-0120, is also a selective URAT1 inhibitor rather than a xanthine oxidase inhibitor. InventisBio has evaluated it as monotherapy and in combination with allopurinol. Combination use could become commercially important among patients who need both reduced uric acid production and increased renal excretion.

Pozdeutinurad, formerly AR882, is one of the most advanced competitive assets. In Sobi’s REDUCE 2 Phase III study, 69.2% of patients receiving 75 mg and 56.6% receiving 50 mg achieved serum urate below 6 mg/dL at month six, compared with 8.1% in the control group. The program targets a broader progressive-gout population than the infusion-eligible refractory segment, giving it a larger potential commercial base if pivotal development and regulatory review remain on track.

 

Immune-Tolerant Uricase Development Faces a Manufacturing Barrier

NASP, formerly SEL-212, combines pegadricase with nanoencapsulated sirolimus intended to reduce anti-drug antibody formation. The program seeks to extend uricase activity and move severe gout treatment toward once-monthly administration.

The FDA issued a Complete Response Letter in June 2026 requesting additional chemistry, manufacturing, and control information and identifying deficiencies involving contract manufacturing facilities. The agency did not identify clinical efficacy or safety issues affecting approvability. A successful resubmission could create a monthly competitor in uncontrolled gout, while the delay protects the current position of pegloticase.

 

NLRP3 Inhibition Opens a Separate Flare-Treatment Route

Dapansutrile targets the NLRP3 inflammasome activated by urate crystals during an acute gout attack. Its role differs from urate-lowering therapy because it addresses inflammation and pain rather than reducing the uric acid burden.

Commercially, the asset would compete with colchicine, nonsteroidal anti-inflammatory drugs, and corticosteroids. It could also complement long-term therapy because patients may continue to flare during treatment initiation or while serum urate remains above target. Success will depend on speed of symptom relief, safety in patients with kidney and cardiovascular comorbidities, and differentiation from inexpensive established anti-inflammatory medicines.

 

Treatment Escalation Will Decide Market Growth

The market’s expansion depends less on treating every person with elevated serum urate and more on improving control among diagnosed gout patients. Low initiation, interrupted therapy, insufficient dose titration, and limited monitoring leave many patients exposed to repeated attacks and progressive crystal deposition.

Generic allopurinol will continue to dominate treatment volume, but faster revenue growth will come from selective URAT1 inhibitors, combination oral regimens, premium refractory-gout biologics, and hospital-based management of tumor lysis syndrome. North America will remain the leading high-value market, while Asia Pacific will shape oral innovation and regional expansion.

 

Hyperuricemia Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.65 Billion
Revenue Forecast in 2032	USD 10.14 Billion
Overall Growth Rate	CAGR of 8.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Clinical Type, By Route of Administration, By Distribution Channel, By Geography
By Drug Class	Xanthine Oxidase Inhibitors, Uricosuric / URAT1 Inhibitors, Uricase-Based Biologics, Anti-Inflammatory Gout Flare Therapies, Combination Therapies
By Clinical Type	Asymptomatic Hyperuricemia, Gout-Associated Symptomatic Hyperuricemia, Refractory / Uncontrolled Gout, Tumor Lysis Syndrome-Associated Hyperuricemia, Uric Acid Stone and Kidney-Associated Hyperuricemia
By Route of Administration	Oral, Injectable
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Channels
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising prevalence of gout and metabolically associated hyperuricemia Persistent treatment and serum urate control gaps Growing use of selective URAT1 inhibitors and combination therapies
Customization Option	Available upon request